SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest, shifting ecosystem management, and ongoing discussions regarding its quantum-resistant technology. While some traders debate the asset's long-term viability following historic price volatility, active participants are heavily focused on potential regulatory catalysts and the ongoing expansion of its real-world asset (RWA) utility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is currently trending due to intense volatility following a quarterly earnings report that featured a strong double beat on top and bottom lines but provided cautious forward revenue guidance. The community is actively debating whether the double-digit price decline is a baseless overreaction caused by market makers or a justified correction given the stock's high valuation and competitive concerns within the AI infrastructure sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh the potential impact of looming pharmaceutical tariffs, which are pushing the company to increase its U.S. manufacturing footprint. Simultaneously, the community is actively debating the company's aggressive M&A strategy, particularly its focus on expanding oncology and T-cell engager therapy pipelines, while keeping a watchful eye on patent litigation risks.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability, with supporters pointing to upcoming regulatory clarity like the Clarity Act and existing infrastructure partnerships, while skeptics emphasize a prolonged downward price trend and lack of active communication from project leadership.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is a primary focal point of market discourse following the FDA approval of Foundayo, its once-daily oral GLP-1 weight-loss pill, which analysts view as a major step toward expanding the obesity treatment market through improved convenience and scalability. While community discussion remains intense regarding its competitive positioning against Novo Nordisks oral offerings, the broader pharma sector is also digesting the implications of potential new pharmaceutical tariff policies and ongoing M&A activity, keeping Eli Lillys valuation and long-term growth trajectory at the center of investor focus.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing significant market activity and heightened community discourse driven by persistent acquisition rumors and notable institutional volume in after-hours trading. Traders are actively debating the stock's valuation relative to its rare disease pipeline, while observing unconventional trading patterns that have fueled speculation of a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tecogen Inc. (TGEN) Reports Q4 Loss, Tops Revenue Estimates

Tecogen (TGEN) delivered earnings and revenue surprises of +10.00% and +12.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The company reported revenues of $27.07 million for the year ended Dec. 31, 2025 compared to $22.62 million for the same period in 2024, an increase in revenues of 19.7% year over year.</li><li>The rise in FY25 revenue was helped by a 105.5% jump in its products revenues.</li><li>Its net loss of $8.25 million for FY25 widened compared to $4.76 million for the same period in 2024.</li></ul><p>Tecogen (TGEN) stock jumped 6% during extended hours of trading on Tuesday after it reported its full year 2025 results that beat Wall Street expectations.&nbsp;</p><p>The company reported revenues of $27.07 million for the year&nbsp;ended Dec. 31, 2025, compared to $22.62 million for the same period in 2024, an increase in revenues of 19.7% year over year, helped by a 105.5% jump in its products revenues. Analysts expected revenue of $26.49 million, as per data from Stocktwits.&nbsp;</p><p>However, its net loss of $8.25 million for FY25 widened compared to $4.76 million for the same period in 2024. The loss increased due to the impairment of goodwill and long-lived assets, increased operating expenses and decreased gross profit from&nbsp;its&nbsp;Services segments,&nbsp;the company said.&nbsp;</p><p>“Our revenue grew 20% year on year. Although our loss widened and cash burn increased, this was because of critical expenses needed to expand margins in the service business and to develop the data center opportunities including expanding manufacturing capacity, R&amp;D on our data center dual power source chiller and marketing," said Abinand Rangesh, CEO of Tecogen.</p><h2 class="st-heading-2">Quarter Performance</h2><p>Revenues for the fourth quarter were $5.32 million compared to $6.08 million for the same period in 2024, a 12.5% decrease due to weakness in its products segment.&nbsp;</p><p>However, Services revenues in the quarter came at $4.46 million, compared to $4.08 million for the same period in 2024, an increase of 9.3% due to a $0.36 million increase in revenues from existing contracts and a $0.01 million increase in revenues from the acquired Aegis maintenance contracts, the company said.&nbsp;</p><p>The company reported a loss per share of $0.13 per share in the fourth quarter, compared to $0.05 per share from the year-ago quarter. Analysts on average expected a loss per share of $0.10 according to data from Stocktwits.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around TGEN stock trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company have fallen nearly 44% year to date.&nbsp;</p>

Retail sentiment around TGEN stock trended in ‘neutral’ territory amid ‘high’ message volume. 

Why Is TGEN Stock Rising After Hours?

Tecogen reported full year 2025 results on Tuesday, with revenue beating Wall Street expectations. 

Equity

Tecogen reported full year 2025 results on Tuesday, with revenue beating Wall Street expectations. 


Aaon (AAON) Misses Q4 Earnings Estimates

Aaon (AAON) delivered earnings and revenue surprises of -12.85% and +14.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Comfort Systems (FIX) Q4 Earnings and Revenues Beat Estimates

Comfort Systems (FIX) delivered earnings and revenue surprises of +38.34% and +15.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Can Mechanical & Electrical Strength Support Comfort Systems in 2026?

FIX enters 2026 with surging mechanical and electrical revenues, a record backlog and tech-driven demand supporting earnings stability.

Does Comfort Systems' Cash Strength Reinforce Financial Stability?

FIX's growing cash position and disciplined capital strategy reinforce financial stability, supporting dividends, buybacks and flexibility amid ongoing macro uncertainty.

Is Comfort Systems Positioned for Long-Term Pharma Project Demand?

FIX sees rising pharma and life sciences planning activity, signaling a strong long-term pipeline for its specialized mechanical and electrical work.

Aaon (AAON) Surpasses Q3 Earnings and Revenue Estimates

Aaon (AAON) delivered earnings and revenue surprises of +12.12% and +13.66%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Fortune Brands Innovations (FBIN) Misses Q3 Earnings and Revenue Estimates

Fortune Brands Innovations (FBIN) delivered earnings and revenue surprises of -0.91% and -2.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tecogen (TGEN) Soars 26.7%: Is Further Upside Left in the Stock?

Tecogen (TGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tecogen, Inc. engages in the production of commercial and industrial, natural-gas-fueled engine-driven, and combined heat and power (CHP) products. It operates through the Products, Services, and Energy Production segments. The Products segment designs, manufactures, and retails industrial and commercial cogeneration systems. The Services segment installs and maintains the cogeneration systems. The Energy Production segment sells energy in the form of electricity, heat, hot water, and cooling to customers under long-term sales agreements. The company was founded by George N. Hatsopoulos and John N. Hatsopoulos in 1987 and is headquartered in North Billerica, MA.

Tecogen Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

TGEN
Tecogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TGEN News

TGENTecogen Inc